Value Sense
MNPR

Monopar Therapeutics Inc. (MNPR)

Last Price$37.6(6.0%)
Market Cap$1,323.7M

MNPR Rating

MNPR Quality rating
6.2
How this score works?
MNPR Quality rating performance

MNPR Intrinsic Value

Key Highlights:
Relative Value vs Current Share Price
As of Mar 24, 2025 MNPR Relative Value is $1.6, which is overvalued by 95.7%, compared to current share price of $37.6.
DCF Value vs Current Share Price
As of Mar 24, 2025 MNPR DCF Value is N/A, which is undervalued by N/A, compared to current share price of $37.6.
Methodology
Price per share, $
MNPR
Intrinsic value$1.6
Overvalued by95.6%
Current share price
37.6
Relative value
1.6
DCF value
not available

MNPR Share Price History

1W 9.8%
1M 4.5%
6M 752.6%
YTD 1,932.4%
1Y 959.2%
3Y 185.9%
5Y 5.0%
10Y (71.6%)
Share Price
Intrinsic Value
Drawdown
Total Return
vs SP500
vs NASDAQ
Crunching data... Almost there!

MNPR Stock Metrics

Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
Base
Market Cap
$1,323.7M
Enterprise Value
$1,317.6M
LTM Revenue
$0.0
LTM Free Cash Flow
($5,951.6K)
Shares Outstanding
35M
Employees
N/A
Growth (CAGR)
Revenue 5Y
N/A
Operating Income 5Y
11.3%
EPS 5Y
14.91%
Free Cash Flow 5Y
14.1%
Forward Revenue 2Y
N/A
Forward EPS 2Y
152.59%
Profitability
Gross margin
N/A
EBIT margin
N/A
Net income margin
N/A
OCF margin
N/A
FCF margin
N/A
FCF / Net Income
115.1%
Intrinsic Value
Intrinsic Value
$1.6 (95.6% overvalued)
DCF Value
N/A
Relative Value
$1.6
Peter Lynch fair value
($3,383.3)
Ben Graham fair value
($102.2)
Reverse DCF (implied FCF growth)
(100.0%)
EPV, % of EV
(32.7%)
Valuation (LTM)
EV / Revenue
N/A
EV / EBIT
(188.3x)
P / FCF
(222.4x)
P / E
(1.0x)
P / BV
267.6x
PEG
(0.0x)
FCF Yield
(0.4%)
Return on Capital
ROE
(93.7%)
ROA
(78.1%)
ROIC
639.8%
ROCE
(63.2%)
ROE 5Y avg
(72.6%)
ROIC 5Y avg
2,739.0%
ROCE 5Y avg
2,739.0%
Financial Health
Cash & Short-term Investments
$6,020.1K
Net Debt
($6,020.1K)
Net Debt / FCF
1.0x
EBIT / Interest
(77.3x)
Total Debt / Equity
0.0%
Dividends
Dividends per share (DPS)
$0.0
DPS 5Y CAGR
N/A
Dividend Yield
0.0%
FCF Payout ratio
0.0%
Ex-dividend date
Earnings
Next earnings date
May 07, 2025
Last Revenue surprise
MISS by 0.0%
Last EPS surprise
BEAT by (24.3%)
Next EPS YoY growth
0.0%
Last 10 earnings
7 Beat & 3 Miss

MNPR Stock Financials

MNPR Income Statement Metrics

Annual
Quarterly
LTM

Revenue

$0.0 N/A

Operating Income

($8,831,235.0) -16.2% YoY

Net Income

($8,402,196.0) -19.9% YoY

MNPR Cash Flow Statement Metrics

Annual
Quarterly
LTM

Operating Cash Flow (OCF)

($7,858.3K) +8.7% YoY

Capital Expenditure (CAPEX)

$0.0 N/A YoY

Free Cash Flow (FCF)

($7,858.3K) +8.7% YoY

MNPR Income Statement Overview

Annual
Quarterly
LTM
Dec'15
Dec'16
Dec'17
Dec'18
Dec'19
Dec'20
Dec'21
Dec'22
Dec'23
Operating expenses
$8,831.2K (16.2%) YoY
Net income
$8,402.2K (19.9%) YoY
0.0% margin
Other: $8,402.2K
R&D
$5,600.2K (26.2%) YoY
0.0% of revenue
SG&A
$3,231.0K 9.7% YoY
0.0% of revenue

MNPR Balance Sheet Overview

Annual
Quarterly
LTM
Dec'15
Dec'16
Dec'17
Dec'18
Dec'19
Dec'20
Dec'21
Dec'22
Dec'23
Assets
Liabilities
Total assets
$7,345.2K
Current assets ($7,332.5K, 99.8% of total)
Cash & ST investments
$7,266.1K (98.9%)
Other current assets
$66.4K (0.9%)
Non-current assets ($12.6K, 0.2% of total)
Other non-current assets
$0.0 (0.0%)
Financial position
Net Debt
($7,266.1K)
$7,266.1K$0.0
Cash & Short-term Investments
Total Debt
Quick ratio
4.1x
Net Debt to Free Cash Flow
0.9x
Debt to Equity ratio
0.0%

MNPR Stock Ratios

Annual
Quarterly
LTM
Industry Median
5Y Historical Average
Benchmark
Revenue growth
EPS growth
Gross margin
Free Cash Flow margin
Net Debt to FCF
FCF to Interest
ROIC
Shareholder yield

MNPR Earnings Surprises

Crunching data... Almost there!

MNPR Dividends

MNPR Dividend Yield

Crunching data... Almost there!

MNPR Dividend Per Share

3Y
10Y
30Y
Annual
Quarterly
LTM
1Y Growth
N/A
3Y CAGR
N/A
5Y CAGR
N/A
10Y CAGR
N/A

Competing with MNPR

Overview
Ratings
Intrinsic Value
Valuation
Growth
Profitability
Health
Capital allocation
Momentum
Earnings
Dividends
Company name
Market Cap
Quality rating
Intrinsic value
1Y Return
Revenue
Free Cash Flow
Revenue growth
FCF margin
Gross margin
ROIC
Total Debt to Equity
MNPR
$1,323.7M
6.2
$1.6
95.6% overvalued
959.2%
$0.0
($5,951.6K)
N/A
N/A
N/A
639.8%
0.0%
VRTX
$131.8B
5.8
$186.0
63.7% overvalued
23.0%
$11.0B
($790.3M)
11.5%
(7.2%)
86.1%
(15.0%)
10.7%
REGN
$71.1B
6.4
$1,034.1
56.4% undervalued
(31.1%)
$14.2B
$3,597.2M
8.3%
25.3%
84.5%
25.7%
5.7%
ARGX
$43.1B
6.3
$161.4
73.4% overvalued
52.6%
$3,154.8M
($58.8M)
157.1%
(1.9%)
74.8%
67.0%
0.7%
ALNY
$37.4B
5.2
$92.7
68.1% overvalued
91.2%
$2,248.2M
($42.6M)
23.0%
(1.9%)
85.6%
(7.2%)
1,931.9%
BNTX
$24.2B
6.0
$193.7
92.5% undervalued
8.2%
€2,751.1M
(€229.8M)
(28.0%)
(8.4%)
80.3%
(37.8%)
1.3%
RPRX
$15.1B
5.5
$68.9
104.3% undervalued
14.9%
$2,263.9M
$2,769.0M
(3.8%)
122.3%
73.9%
14.5%
73.6%
SMMT
$15.0B
6.0
$0.6
97.2% overvalued
530.8%
$0.0
($142.1M)
N/A
N/A
N/A
(3,335.4%)
1.9%
UTHR
$14.3B
7.8
$542.3
69.6% undervalued
31.0%
$2,877.4M
$1,080.6M
23.6%
37.6%
89.2%
65.4%
4.7%
BMRN
$13.7B
6.8
$50.8
29.4% overvalued
(16.8%)
$2,850.5M
$475.4M
17.8%
16.7%
78.6%
11.0%
10.7%
BGNE
$1,846.9M
5.5
$2,609.6
1,051.1% undervalued
39.9%
$3,316.8M
($1,041.0M)
50.5%
(31.4%)
83.7%
(43.2%)
32.1%

FAQ

What is Monopar Therapeutics Inc. (MNPR) stock rating?

As of today, Monopar Therapeutics Inc. has a stock rating of 6 (out of 10), which is considered Good.

is Monopar Therapeutics Inc. (MNPR) a good stock to buy?

As of today, Monopar Therapeutics Inc. has a Good stock rating, which is 95.6% overvalued. According to Value Sense backtesting, stocks with similar profile tend to underperform the market by 4.6%.